A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

A Phase 1 Study of Recombinant Anti-Epidermal Growth Factor Receptor (EGFR) Human-mouse Chimeric Monoclonal Antibody Injection in Patients With Metastatic Colorectal Cancer

This is an open-label, parallel designed study to assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of a recombinant anti-EGFR monoclonal antibody (CPGJ602) in patients with at least one prior chemical regimen failed metastatic colorectal cancer. The immunogenicity and preliminary efficacy of CPGJ602 will also be assessed. The study includes 3 parts: part 1: after a single dose of CPGJ602 or cetuximab (the active comparator), the patients will be observed for 4 weeks; part 2: CPGJ602 or cetuximab will be administered to the patients once a week for 5 weeks; part 3: CPGJ602 will be administered to the patients once a week until the patient's death or the withdrawal decision of the patient and/or investigator.

Study Overview

• Status: Unknown
• Conditions: Metastatic Colorectal Cancer
• Intervention / Treatment: Biological: CPGJ602; Biological: Cetuximab

Detailed Description

OBJECTIVES:

Primary:

To assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of CPGJ602 administered by intravenous infusion.

Secondary:

To assess the immunogenicity and anti-tumor activity of CPGJ602, compare the pharmacokinetics and immunogenicity between CPGJ602 and the active comparator, cetuximab, and to provide scientific basis for the subsequent phase 2/3 clinical trials.

OUTLINE:

This is an open-label, parallel designed study in patients with at least one prior chemical regimen failed metastatic colorectal cancer. The study can be divided into 3 parts:

Part 1: Single-dose Part

• Arm A: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
• Arm B: CPGJ602, IV over 2 hours, 400 mg/m2 X 1;
• Arm C: Cetuximab, IV over 2 hours, 400 mg/m2 X 1.

Part 2: Multi-dose Part

The subjects from arm A in Part 1 will be randomized into arm B or C.

• Arm B: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
• Arm C: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time. The completion of Day 63 Visit (the visit on the 7th day after the 5th dose in Part 2) can be considered as the completion of the study.

Part 3 (Follow-up Part)

CPGJ602, IV over 1 hour, QW, 250mg/m2, until the patient's death or the withdrawal decision of the patient and/or investigator.

• Study Type: Interventional
• Enrollment (Anticipated): 21
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310020
      • Recruiting
      • Sir Run Run Shaw Hospital
      • Contact: Hongming Pan, Doctor; Phone Number: 0571-86006922; Email: shonco@sina.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 18-70 years old, male or female.
2. Histologically or cytologically confirmed metastatic CRC, and have failed (disease progression or intolerance) at least one prior chemical regimen containing oxaliplatin, irinotecan or 5-FU, etc.
3. ECOG performance status 0 or 1.
4. Estimated life expectancy ≥ 3 months.
5. RAS (including K-ras and N-ras) wide type status.

6. Adequate bone marrow, hepatic and renal functions. Hematopoietic:

   Leukocytes (WBC)>4.0×109/L or Absolute Neutrophil Count (ANC)> 1.5×109/L, Platelet Count (PLT)>80×109/L, Hemoglobin (Hb)>90g/ L; Hepatic: Total Bilirubin (T-Bil)≤1.5×ULT (Upper Limit of Normal), Alanine Transaminase (ALT)/ Aspartate Transaminase (AST)≤2.5×ULT or ≤5×ULT in case of liver metastases; Renal: Blood Urea Nitrogen (BUN)≤1.5×ULT, Serum Creatinine (Cr) ≤ 1.5×ULT.

7. At least one measurable disease based on RECIST criteria (v 1.1).
8. Signed informed consent on a voluntary basis at screening, and no geographical condition that would preclude the study compliance.

Exclusion Criteria:

1. Less than 28 days since prior chemotherapy, radiotherapy or surgery (diagnosis biopsy is allowed).
2. Previous epidermal growth factor receptor (EGFR) targeted therapies (including monoclonal antibody, tyrosine kinase inhibitor [TKI] and other EGFR targeted therapies, such as cetuximab, nimotuzumab, panitumumab, gefitinib, erlotinib, and icotinib, etc.
3. Known hypersensitivity to study drugs or any of the excipients.
4. Known or clinical suspected brain metastases and/or disease of meninges.
5. Clinically significant cardiovascular or cerebrovascular dis ease, history of myocardial infarction (MI) in the latest 6 months, or high-risk of uncontrolled cardiac arrhythmias.
6. History of acute or sub-acute intestinal obstruction, or of inflammatory bowel disease.
7. A serious and uncontrolled concomitant disease which, in the investigator's opinion, rules out the patient's participation in the study, such as history of malignancies other than CRC (with the exception of: curatively treated carcinoma of the skin [except for melanoma]; cured cervical cancer or basal cell skin cancer, ductal carcinoma in situ [DICS], endometrial carcinoma [stage I grade 1]; and other solid tumors including lymphoma without bone marrow infiltration for which the patient has been disease-free for 5 years), uncontrolled hypertension, diabetes mellitus (DM), peripheral neuropathy, and infectious diseases (including viral, bacterial and parasitic infections), etc.
8. Pregnancy or lactation, or a fertility plan during the participation in this study.
9. No more than 4 weeks or no more than 5 times of t1/2 since prior investigational agents.
10. Other situations that impede the patient's participation in the study at the discretion of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CPGJ 602 low dose; Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;	Biological: CPGJ602; Injection, q.w., 20 mg: 100 ml
Experimental: CPGJ 602 normal dose; Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;	Biological: CPGJ602; Injection, q.w., 20 mg: 100 ml
Active Comparator: Cetuximab normal dose; Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.	Biological: Cetuximab; Injection, q.w., 20 mg: 100 ml

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Plasma Concentration [Cmax]	part 1 for single dose and part 2 for multiple doses	Day 0 - Day 21 for single dose and Day 28 - Day 63 for multiple doses
Half life of CPGJ602 in blood [t1/2]	part 1 for single dose and part 2 for multiple doses	Day 0 - Day 21 for single dose and Day 28 - Day 63 for multiple doses
Area Under the Curve [AUC]	part 1 for single dose and part 2 for multiple doses	Day 0 - Day 21 for single dose and Day 28 - Day 63 for multiple doses
Incidence of Adverse Events [AEs]	to evaluate the safety and tolerability	Day -28 to 1 month following the last administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anti-Drug Antibody [ADA]	to evaluate the Immunogenicity; if the result is positive, Neutralizing Antibody [NAB] will also be assessed.	Day 0 to Day 63, and in the follow-up period.
Objective Response Rate [ORR]	the rate of completely response [CR] and partial response [PR] patients	Day -28 - Day 63
Carcinoembryonic antigen [CEA]	Tumor Marker	Day -28 - Day 63
Cancer antigen [CA19-9]	Tumor Marker	Day -28 - Day 63

Collaborators and Investigators

• Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Investigators: Principal Investigator: Jianming Xu, Doctor, the Afflicated Hospital of Academy of Military Medical Sciences

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2017
• Primary Completion (Anticipated): October 30, 2018
• Study Completion (Anticipated): November 30, 2018

Study Registration Dates

• First Submitted: November 9, 2017
• First Submitted That Met QC Criteria: November 22, 2017
• First Posted (Actual): November 29, 2017

Study Record Updates

• Last Update Posted (Actual): September 17, 2018
• Last Update Submitted That Met QC Criteria: September 13, 2018
• Last Verified: November 1, 2017

More Information

Terms related to this study

• Keywords: Metastatic Colorectal Cancer,; Recombinant Anti-EGFR Monoclonal Antibody
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Cetuximab
• Other Study ID Numbers: CPGJ602-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No